Analysis has announced the addition of “Diabetes Drug Delivery Devices Market, 2020-2030” report to its list of
engaged in this domain are presently focusing on introducing advanced features,
such as integrated continuous glucose monitoring (CGM) systems, artificial
intelligence (AI) enabled algorithms, provisions for audiovisual / tactile
feedback, and automatic drug reconstitution features. Such efforts are
primarily directed towards differentiating proprietary offerings within a
highlight competitive market landscape, and are expected to drive the market’s
growth over the coming years.
than 80 diabetes drug delivery devices are presently available / under
More than 65% of the aforementioned devices are marketed,
while the rest are being evaluated in preclinical / clinical studies. It is
also worth highlighting that majority of the drug delivery devices intended for
diabetics are insulin pumps (35%), followed by pen injectors / autoinjectors
50 companies, across the world, claim to be engaged in developing drug delivery
devices for diabetics
Majority (44%) of the device developers are located in
North America, primarily in the US. Within Europe, most of the developers are
distributed across France, Germany, Switzerland, Italy and UK. Further, around
37% of the players engaged in this domain are large firms.
market is dominated by the products of big pharma players
The leading pharmaceutical companies (in terms of number
of products and revenues shares) involved in this domain are large / very large
businesses. It is worth mentioning that the aforementioned players are
investing significantly in terms of number of marketed and clinical-stage
drugs, partnerships and strategic investments in this domain.
activity in this domain has grown at a CAGR of 33%, between 2015 and 2019
Maximum number of partnerships were reported in 2018.
Majority of the agreements captured in the report, were observed to be related
to technology integration deals (over 35%), followed by product development
America and Europe are anticipated to capture over 60% of the overall market
share by 2030
The current market is driven by the sales of diabetes
drug delivery devices designed for subcutaneous administration (over 70%),
followed by those that facilitate intravenous administration (26%). Further,
pen injectors / autoinjectors currently capture 52% of the overall market share
(in terms of sales revenues).
Latest Market Insights:
Diabetes Drug Delivery Devices Market is projected to be over USD 31 billion by 2030
Who are the leading players engaged in the development of
diabetes drug delivery devices?
What are the popular devices types that are available /
under development for the delivery of diabetes medicine?
What kind of novel / advanced features are device
developers incorporating into their proprietary offerings in order to maintain
a competitive edge in the market?
What kind of partnership models are commonly being
adopted by stakeholders in this industry?
What is the role of big pharma companies in this market?
What are the factors that are likely to influence the
evolution of this market?
How is the current and future market opportunity likely
to be distributed across key market segments?
USD 31 million (by 2030) financial opportunity within the diabetes drug
delivery devices market has been analyzed across the following segments:
of the Device
Rest of the World
research covers detailed profiles of key players (listed below); each profile
features an overview of the company, financial information (if available),
details related to its technology portfolio, product portfolio, recent
developments, and an informed future outlook.
Customized Report: Global Diabetes Drug Delivery Devices Market Size 2030